RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2, and PTK6-Mediated Cell Survival

Prostate cancer has a proclivity to metastasize to bone. The mechanism by which prostate cancer cells are able to survive and progress in the bone microenvironment is not clear. Identification of molecules that play critical roles in the progression of prostate cancer in bone will provide essential targets for therapy. Ribosomal S6 protein kinases (RSK) have been shown to mediate many cellular functions critical for cancer progression. Whether RSK plays a role in the progression of prostate cancer in bone is unknown. IHC analysis of human prostate cancer specimens showed increased phosphorylation of RSK in the nucleus of prostate cancer cells in a significant fraction of human prostate cancer bone metastasis specimens, compared with the primary site or lymph node metastasis. Expression of constitutively active myristylated RSK in C4-2B4 cells (C4-2B4/RSK) increased their survival and anchorage-independent growth compared with C4-2B4/vector cells. Using an orthotopic bone injection model, it was determined that injecting C4-2B4/RSK cells into mouse femurs enhanced their progression in bone compared with control cells. In PC3-mm2 cells, knockdown of RSK1 (RPS6KA1), the predominant RSK isoform, but not RSK2 (RPS6KA2) alone, decreased anchorage-independent growth in vitro and reduced tumor progression in bone and tumor-induced bone remodeling in vivo. Mechanistic studies showed that RSK regulates anchorage-independent growth through transcriptional regulation of factors that modulate cell survival, including ING3, CKAP2, and PTK6. Together, these data provide strong evidence that RSK is an important driver in prostate cancer progression in bone. Implications: RSK, an important driver in prostate cancer progression in bone, has promising potential as a therapeutic target for prostate cancer bone metastasis. Mol Cancer Res; 13(2); 348–57. ©2014 AACR.

[1]  S. Eccles,et al.  Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. , 2009, The American journal of pathology.

[2]  J. Blenis,et al.  The RSK family of kinases: emerging roles in cellular signalling , 2008, Nature Reviews Molecular Cell Biology.

[3]  W. Hahn,et al.  PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival , 2010, PloS one.

[4]  R. Kobayashi,et al.  Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation , 2010, Proceedings of the National Academy of Sciences.

[5]  J. Ostrander,et al.  Brk/PTK6 signaling in normal and cancer cell models. , 2010, Current opinion in pharmacology.

[6]  J. Ramos,et al.  RSK isoforms in cancer cell invasion and metastasis. , 2013, Cancer research.

[7]  E. Ruoslahti,et al.  Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. , 1990, Cell.

[8]  G. Stein,et al.  Integrin Α V Β 6 Promotes an Osteolytic Program in Cancer Cells by Upregulating Mmp2 , 2022 .

[9]  G. Fang,et al.  CKAP2 Is a Spindle-associated Protein Degraded by APC/C-Cdh1 during Mitotic Exit* , 2007, Journal of Biological Chemistry.

[10]  P. Cohen,et al.  Identification of Regulatory Phosphorylation Sites in Mitogen-activated Protein Kinase (MAPK)-activated Protein Kinase-1a/p90 rsk That Are Inducible by MAPK* , 1998, The Journal of Biological Chemistry.

[11]  G. Heijne,et al.  Structural Bioinformatics-Based Design of Selective , Irreversible Kinase Inhibitors , 2005 .

[12]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[13]  M. Ljungman,et al.  p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. , 2010, Cancer research.

[14]  Philippe P Roux,et al.  Regulation and function of the RSK family of protein kinases. , 2012, The Biochemical journal.

[15]  J. Blenis,et al.  Characterization of Regulatory Events Associated with Membrane Targeting of p90 Ribosomal S6 Kinase 1 , 2001, Molecular and Cellular Biology.

[16]  J. Yokota,et al.  A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis , 2003, Oncogene.

[17]  W. Bornmann,et al.  RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B , 2014, Oncogene.

[18]  D. Lannigan,et al.  Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability. , 2012, Bioorganic & medicinal chemistry letters.

[19]  A. Tyner,et al.  Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. , 2010, Biochimica et biophysica acta.

[20]  P. Cohen,et al.  BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. , 2007, The Biochemical journal.

[21]  T. Nguyen.  Targeting RSK: an overview of small molecule inhibitors. , 2008, Anti-cancer agents in medicinal chemistry.

[22]  Timothy M. Errington,et al.  The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. , 2005, Cancer research.

[23]  F. Giancotti,et al.  Elevated levels of the α 5 β 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells , 1990, Cell.

[24]  D. Lannigan,et al.  Improving the affinity of SL0101 for RSK using structure-based design. , 2013, ACS medicinal chemistry letters.

[25]  C. Logothetis,et al.  Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone , 2008, Molecular Cancer Research.

[26]  C. Logothetis,et al.  Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. , 2010, Cancer research.

[27]  Edward L. Huttlin,et al.  Gab2 Phosphorylation by RSK Inhibits Shp2 Recruitment and Cell Motility , 2013, Molecular and Cellular Biology.

[28]  C. Bakal,et al.  Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner. , 2005, Cancer research.

[29]  Joobae Park,et al.  Functional Importance of the Anaphase-Promoting Complex-Cdh1-Mediated Degradation of TMAP/CKAP2 in Regulation of Spindle Function and Cytokinesis , 2007, Molecular and Cellular Biology.

[30]  Timothy M. Errington,et al.  Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. , 2005, Cancer research.

[31]  J. Taunton,et al.  p90 RSK2 Mediates Antianoikis Signals by both Transcription-Dependent and -Independent Mechanisms , 2013, Molecular and Cellular Biology.

[32]  E. Gelmann,et al.  p53 oncogene mutations in three human prostate cancer cell lines , 1993, The Prostate.

[33]  O. Pardo,et al.  The p90 RSK family members: common functions and isoform specificity. , 2013, Cancer research.

[34]  S. Weremowicz,et al.  RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation , 1995, Molecular and cellular biology.

[35]  J. Blenis,et al.  Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Moller,et al.  Divergent Functional Roles for p90rsk Kinase Domains (*) , 1995, The Journal of Biological Chemistry.

[37]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.